Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPDDPIPELINEPressRett Syndrome
Feb222021

Anavex Life Sciences Announces Participation at Upcoming Worldwide National Institutes of Health (NIH) Panel at Rare Disease Day®

February 22, 2021
Feb112021

Anavex Life Sciences Reports Fiscal 2021 First Quarter Financial Results And Business Outlook  

February 11, 2021
Feb82021

Anavex Life Sciences to Announce Fiscal 2021 First Quarter Financial Results and Business Outlook on Thursday, February 11, 2021

February 8, 2021
Jan112021

Anavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX®2-73 (blarcamesine) in People with Parkinson’s Disease

January 11, 2021
Jan62021

Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect Conference

January 6, 2021
Dec282020

Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates

December 28, 2020
Dec222020

Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020

December 22, 2020
Dec152020

Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome

December 15, 2020
Nov302020

Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome and other Neurodevelopmental Disorders

November 30, 2020
Nov252020

Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference

November 25, 2020
Nov62020

Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD 2020 Conference

November 6, 2020
Oct152020

Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia

October 15, 2020
12345…
6789101112131415161718
19

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top